Komipharm International (041960) Fundamentals 2026 — Revenue Analysis | SniperIQ
Komipharm International (041960) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩508.9B, trading at ₩7080.00 on the KOE. This SniperIQ fundamentals page covers Komipharm International's valuation, profitability (net margin -12.8%), revenue (₩52.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Komipharm International's market cap?
Komipharm International (041960) has a market capitalization of approximately ₩508.9B, trading at ₩7080.00 on the KOE. Market cap moves with the live share price.
What is Komipharm International's P/E ratio?
Komipharm International's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Komipharm International?
Komipharm International runs a net profit margin of -12.8%, a gross margin of 32.7%, and an operating margin of 2.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Komipharm International generate?
Komipharm International reported revenue of ₩52.5B for fiscal year 2025, with net income of -₩7.2B and earnings per share (EPS) of -100.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Komipharm International pay a dividend?
Komipharm International does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Komipharm International financially healthy?
Komipharm International carries a debt-to-equity ratio of 0.57x and a current ratio of 1.31x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Komipharm International a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Komipharm International (041960) the key facts are: market cap ₩508.9B, revenue ₩52.5B, 52-week range 5140-10790. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Komipharm International's full fundamentals live
Get Komipharm International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.